Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study (Q46414306)
Jump to navigation
Jump to search
scientific article published in August 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study |
scientific article published in August 2008 |
Statements
1 reference
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study (English)
1 reference
Jean-Michel Molina
1 reference
Jaime Andrade-Villanueva
1 reference
Juan Echevarria
1 reference
Ploenchan Chetchotisakd
1 reference
Jorge Corral
1 reference
Neal David
1 reference
Graeme Moyle
1 reference
Marco Mancini
1 reference
Lisa Percival
1 reference
Rong Yang
1 reference
Alexandra Thiry
1 reference
Donnie McGrath
1 reference
CASTLE Study Team
1 reference
1 August 2008
1 reference
1 reference
372
1 reference
646-655
1 reference
9639
1 reference
Identifiers
1 reference
1 reference